Find Locations
For hours, walk-ins and appointments.
May 22-24 | 5月22-24日
International Cell and Gene Therapy China Summit and Exhibition
国际细胞与基因治疗中国峰会暨展览会
Nanjing Yangtze River International Conference
南京扬子江国际会议中心,南京,江苏
Join us at CGCS 2024 | 邀您莅临 CGCS 2024
Booth T01 | 展位 T01
Your science-driven laboratory partner to power your global CGT clinical trials
As laboratory partner for all six FDA-approved CAR T therapies and all eight FDA-approved gene-replacement therapies, Labcorp invites you to meet with us at CGCS 2024 for a deeper exchange of ideas. As the strategic partner of CGCS 2024, Labcorp will also host a closed-door meeting with biotechs to share global success stories of CGT development and discuss the complexities of CGT development.
PRESENTATION
Gene therapy capabilities: How a laboratory can provide regulatory support
Thursday, May 23, 2024 | 11:45 a.m. – 12:10 p.m. GMT+8
Location: Main Forum
Sian Estdale
Executive Director and Head of Scientific Affairs, Labcorp
Dr. Sian Estdale joined Labcorp in 2002 and is head of scientific affairs for Labcorp Central Laboratory Services, Bioanalytical Services and Biopharmaceutical Chemistry, Manufacturing and Control Services. She has more than 20 years of industry experience and more than 10 years of experience as a lecturer and researcher in biomedical sciences at Bradford and Sheffield Hallam universities. She has authored more than 60 peer-reviewed papers and industry presentations. Sian co-leads a master’s course in biopharmaceutical development at Leeds University, where she is also chair for the academic industrial board. For more than 10 years, she has been part of the scientific committee of the BioPharmaceutical Emerging Best Practices Association.
PRESENTATION
Key strategies to address the unique challenges of global cell and gene therapy development
Thursday, May 23, 2024 | 2:25 – 2:50 p.m. GMT+8
Location: Gene Therapy Forum
Ningchun Liu
Director of Enterprise Cell and Gene Therapy, Labcorp
Dr. Ningchun Liu provides leadership and guidance to integrated global teams on clients' cell and gene therapy programs. Dr. Liu applies expertise in drug discovery, translational research, immuno-oncology, biomarker identification, assay development and technology implementation, in addition to cell and gene therapy, to lead the development of new products for clients. He also delivers training to team members and other stakeholders on cell and gene therapy and other innovations in cancer research. Before joining Labcorp, Dr. Liu was principal scientist and senior manager for global product development and supply at Bristol Myers Squibb, where he led the ideation, technical development and launch of T-cell (CAR T) therapies. His PhD is in pathology and laboratory medicine from the University of Rochester.
Meet our subject matter expert
Lingchen (Lisa) Guo, PhD
Senior Scientist, Scientific Affairs, Labcorp
Dr. Lingchen Guo is part of the scientific engagement team within scientific affairs as a senior scientist, joining Labcorp in April 2021. She supports business development directors and clients with their portfolio needs and evolving expectations and provides central-laboratory-focused expertise to build a connected scientific community within Asia, Europe and the United States. Lingchen holds bachelor’s and master’s degrees in biochemistry and molecular biology from Wuhan University and a PhD in genetics from Fudan University. Prior to joining Labcorp, she worked in molecular biology, oncology and molecular pharmacology research and then gained further experience in genomics and central laboratories with a number of biotechnology companies.